Comparative bioavailability of a generic capsule formulation of the reverse transcriptase inhibitor efavirenz and the innovator product.

Marier, J F; Morin, I; Al-Numani, D; Stiles, M; Morelli, G; Tippabhotla, S K; Vijan, T; Singla, A K; Garg, M; Di Marco, M; Monif, T

Marier, J F; Morin, I; Al-Numani, D; Stiles, M; Morelli, G; Tippabhotla, S K; Vijan, T; Singla, A K; Garg, M; Di Marco, M; Monif, T.

Affiliation

Marier JF; MDS Pharma Services, St-Laurent (Montréal), Quebec, Canada.

Int J Clin Pharmacol Ther ; 44(4): 180-4, 2006 Apr.

Article in En | MEDLINE | ID: mdl-16625987

Subject(s)

Oxazines/administration & dosage; Oxazines/pharmacokinetics; Reverse Transcriptase Inhibitors/administration & dosage; Reverse Transcriptase Inhibitors/pharmacokinetics; Administration, Oral; Adolescent; Adult; Alkynes; Benzoxazines; Biological Availability; Capsules; Cross-Over Studies; Cyclopropanes; Drugs, Generic; Female; HIV Infections/drug therapy; Humans; Male; Middle Aged

Search on Google

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Oxazines / Reverse Transcriptase Inhibitors Type of study: Clinical_trials / Prognostic_studies Limits: Adolescent / Adult / Female / Humans / Male / Middle aged Language: En Journal: Int J Clin Pharmacol Ther Journal subject: FARMACOLOGIA / TERAPIA POR MEDICAMENTOS Year: 2006 Type: Article Affiliation country: Canada

Search on Google

XML

PubMed Links